Share this video  

ASCO 2022 | How can MRD guide treatment of AML?

Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, reflects on how measurable residual disease (MRD) testing can be used to guide the treatment and management of patients with acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter